ERBB2 and neoplasm: At the last San Antonio symposium, Reinert et al. reported in a cohort of 122 TNBC patients, a higher, although non-statistically significant, pCR rate in HER2-0 versus HER2-low tumours (56% vs. 39%, p = 0.09) [46].